Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Collaboration Agreement [Abstract]

Summary of Activity and Reimbursement Amounts Related to Collaboration Agreement

The following table summarizes the Company’s proportionate share of the activity under the Biogen Collaboration Agreement accounted for under Topic 808, including activities associated with the sale of ZURZUVAE in the U.S., as well as ongoing costs related to the development of SAGE-217 and SAGE-324, as reflected in our statement of operations and comprehensive loss:

	Year Ended December 31,
	2023		2022		2021
	(in thousands)
Collaboration revenue - related party	$	824	$	—	$	—
Cost of revenues		504		—		—
Research and development expenses		94,325		86,028		84,221
Selling, general and administrative expenses		89,599		51,870		18,425

The revenue, cost and expense categories in the table above reflects the following reimbursement amounts to (from) Biogen to account for the sharing of economics under the Biogen Collaboration Agreement:

	Year Ended December 31,
	2023			2022			2021
	(in thousands)
Collaboration revenue - related party	$	(824	)	$	—		$	—
Cost of revenues		504			—			—
Research and development expenses		(76,208	)		(73,227	)		(79,848	)
Selling, general and administrative expenses		16,496			(2,230	)		(11,282	)